M&A Deal Summary |
|
|---|---|
| Date | 2018-01-23 |
| Target | Enochian Biopharma |
| Sector | Life Science |
| Buyer(s) | Renovaro |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2011 |
| Sector | Life Science |
| Employees | 10 |
Renovaro is a biotechnology company focused on developing innovative platforms for gene-modified cellular and immune therapies to cure and treat diseases that kill millions of people each year. Renovaro' VIVA, a Phase III clinical trial MCV is adjuvant immunotherapy that is designed to prevent colon cancer recurrence after standard of care surgery and chemotherapy. Renovaro was founded in 2011 and is based in Los Angeles, California.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| State: California M&A | 2 of 2 |
| Country: United States M&A | 2 of 2 |
| Year: 2018 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-04-05 |
OncoSynergy
San Francisco, California, United States OncoSynergy is a developer of novel oncology drug candidates including the first-in-class FDA orphan drug designated anti-CD29 monoclonal antibody, OS2966. |
Buy | - |